Open access
257
Views
7
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
Angelo RuggieroSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyCorrespondence[email protected]
https://orcid.org/0000-0002-4658-7391View further author information
Gabriella FabbrocicniSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyView further author information
, Sara CacciapuotiSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyView further author information
, Luca PotestioSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
https://orcid.org/0000-0001-5940-0592View further author information
Lucia GalloSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyView further author information
& Matteo MegnaSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyView further author information
Pages 529-536
|
Received 05 Jan 2023, Accepted 22 Feb 2023, Published online: 27 Feb 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.